Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and
Pericardium since the 2015 WHO Classification include the following:(1) pleural and …

Mesothelial tumors are classified into benign or preinvasive tumors, and mesotheliomas.
The benign or preinvasive group includes adenomatoid tumors, well-differentiated papillary …

Cancer cells employ various mechanisms to evade and suppress anti-cancer immune
responses generating a “cold” immunosuppressive tumour microenvironment. Oncolytic …

The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with
malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational …

Introduction Given the emergence of combination of programmed cell death protein-1 and
CTLA4 pathway blockade as effective treatment options in malignant pleural mesothelioma …

Background: The prognostic value of programmed death-ligand 1 (PD-L1) expression in
patients with malignant pleural mesothelioma (MPM) has been controversial according to …

Introduction We investigated the efficacy and toxicity of pembrolizumab in patients with
mesothelioma from a real-world Australian population. We aimed to determine clinical …

Background Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM)
management and treatment assignment. Aim of this study was to identify simple prognostic …

Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as
follows: To assess the effects of immune checkpoint inhibitors (single‐agent or combination …

Objective Programmed death ligand 1 (PD-L1) has been reported to be connected to
prognosis in individuals with malignant pleural mesothelioma (MPM), although there is no …